Oncolytics Biotech (NASDAQ:ONCY) Upgraded by Raymond James to Moderate Buy Rating

Oncolytics Biotech (NASDAQ:ONCY) was upgraded by stock analysts at Raymond James to a “moderate buy” rating in a note issued to investors on Thursday,Zacks.com reports. Raymond James also issued estimates for Oncolytics Biotech’s Q4 2024 earnings at ($0.09) EPS, FY2024 earnings at ($0.32) EPS, Q1 2025 earnings at ($0.09) EPS and FY2025 earnings at ($0.34) EPS.

ONCY has been the subject of several other reports. HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Oncolytics Biotech in a research note on Thursday. Leede Financial lowered Oncolytics Biotech from a “strong-buy” rating to a “moderate buy” rating in a research report on Wednesday.

Oncolytics Biotech Stock Down 3.0 %

NASDAQ:ONCY traded down $0.03 during trading hours on Thursday, reaching $0.98. 245,358 shares of the company’s stock were exchanged, compared to its average volume of 328,224. The company has a market capitalization of $75.53 million, a P/E ratio of -3.63 and a beta of 1.69. Oncolytics Biotech has a 12 month low of $0.84 and a 12 month high of $1.75. The business’s 50-day simple moving average is $1.09 and its two-hundred day simple moving average is $1.06.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Oncolytics Biotech stock. Virtu Financial LLC bought a new stake in shares of Oncolytics Biotech Inc. (NASDAQ:ONCY) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 51,889 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 0.07% of Oncolytics Biotech at the end of the most recent reporting period. 6.82% of the stock is currently owned by institutional investors and hedge funds.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.